UK Biotech Orchard Primes $200M IPO Led By Goodwin
London-based biotechnology firm Orchard Rx Ltd., represented by Goodwin Procter LLP, set a price range on an estimated $200 million initial public offering on Tuesday, joining an IPO pipeline that heavily...To view the full article, register now.
Already a subscriber? Click here to view full article